Phase 2 Clinical Study in Psoriasis With Oral Investigational Drug VX-765

This study has been completed.
Sponsor:
Information provided by:
Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier:
NCT00205465
First received: September 13, 2005
Last updated: December 3, 2007
Last verified: December 2007
  Purpose

To evaluate the safety and tolerability of VX-765 in subjects with chronic plaque psoriasis treated for 28 days.


Condition Intervention Phase
Psoriasis
Drug: VX-765
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of VX-765 in Subjects With Chronic Plaque Psoriasis Requiring Systemic Therapy

Resource links provided by NLM:


Further study details as provided by Vertex Pharmaceuticals Incorporated:

Primary Outcome Measures:
  • Incidence of adverse events
  • Abnormal laboratory values
  • Abnormal ECGs and vital signs

Secondary Outcome Measures:
  • PK/PD
  • Target lesion score after 28 days of treatment
  • Proportion of subjects meeting "clear" or "almost clear" criteria utilizing a static Physician's Global Assessment (sPGA)
  • Proportion of subjects demonstrating ≥ 50% and ≥ 75% decrease from baseline in Psoriasis Area and Severity Index (PASI) to the end of 28 days of treatment
  • Change in PASI from baseline to the end of 28 days of treatment

Estimated Enrollment: 64
Study Start Date: December 2004
Study Completion Date: September 2005
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Diagnosed with chronic plaque psoriasis for at least 6 months
  • Prior systemic therapy

Exclusion Criteria:

  • Current or prior history of illness precluding use of immunomodulatory therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00205465

Sponsors and Collaborators
Vertex Pharmaceuticals Incorporated
Investigators
Study Director: Robert Kauffman, MD, PhD Vertex Pharmaceuticals Incorporated
  More Information

No publications provided

Responsible Party: Robert Kauffman, M.D., Ph.D, Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov Identifier: NCT00205465     History of Changes
Other Study ID Numbers: VX04-765-301
Study First Received: September 13, 2005
Last Updated: December 3, 2007
Health Authority: United States: Food and Drug Administration
Canada: Health Canada

Additional relevant MeSH terms:
Psoriasis
Skin Diseases
Skin Diseases, Papulosquamous

ClinicalTrials.gov processed this record on October 30, 2014